Aegerion Pharmaceuticals, Inc.

Company Name:
Aegerion Pharmaceuticals, Inc.  
Transaction Type:
Follow-on Offering 
Ticker Symbol:
Deal Amount:
Transaction Date:
Transaction Summary:
Aegerion Pharmaceuticals, Inc. raised $50.2 million in its follow-on offering at $14.75 per share. Needham acted as a co-manager on the transaction. The net proceeds from the sale of the shares from the offering will be used by Aegerion Pharmaceuticals, Inc. to fund activities directed at gaining approval of its NDA submission with the FDA and its MAA submission with the EMA, including: • pre-commercial and commercial activities relating to launching lomitapide for the treatment of patients with HoFH in the United States, the European Union, if approved, and in other countries where lomitapide is approved as a treatment for HoFH; • expansion of operations in certain countries; • advancement of the clinical development of lomitapide for the treatment of pediatric and adolescent patients with HoFH and of adult patients with FC; and • to fund working capital, capital expenditures and other general corporate purposes. 
Company Description:
Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR) is committed to changing the way rare, life-threatening disorders are treated. Aegerion is an emerging biopharmaceutical company focused on the development and commercialization of novel, life-altering therapeutics to treat debilitating and often fatal rare diseases. Aegerion is motivated by its commitment to patients first. Aegerion is also attentive to its core values of integrity, innovation, responsibility to healthcare providers, development of employees and always – scientific and clinical excellence. 
Investment Banking